首页> 美国卫生研究院文献>Hospital Pharmacy >Guidelines for the Safe Preparation of Sterile Compounds: Results of the ISMP Sterile Preparation Compounding Safety Summit of October 2011
【2h】

Guidelines for the Safe Preparation of Sterile Compounds: Results of the ISMP Sterile Preparation Compounding Safety Summit of October 2011

机译:安全制备无菌化合物的准则:2011年10月ISMP无菌制备化合物安全峰会的结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Significant patient safety incidents related to sterile drug compounding have occurred for many years. Previous guidelines have focused on ensuring sterility, but serious compounding errors have occurred as well. National efforts are needed to identify and reduce the potential for such errors and their causative factors. In response, the Institute for Safe Medication Practices (ISMP) convened in October 2011 a summit of 60 invited experts in the field for the purpose of establishing by consensus guidelines, safe practices, and standard operating procedures needed to ensure the safe preparation of compounded sterile preparations, especially intravenous admixtures. The resulting guidelines were categorized into 14 core processes: policies and procedures, order entry and verification, drug storage, assembling products and supplies, compounding, drug conservation during drug shortages, preparation of source/bulk containers, technology/automation used, IV workflow software, automated IV compounding devices, quality control/final verification, product labeling, record keeping, and staff management. They were also classified into 3 levels: mandatory, standard, and recommendation. The guidelines presented in this article were felt to be applicable to any health care organization that prepares sterile compounded products. The consensus of the group was that adherence to these guidelines will improve the safety of sterile product compounding and reduce harmful errors in patients receiving these products. Incorporation of these guidelines into sterile compounding practices of health care organizations is an important component of improving patient safety.
机译:与无菌药物配制相关的重大患者安全事件已经发生了很多年。先前的指南着重于确保无菌性,但是也发生了严重的复合错误。需要作出国家努力,以查明并减少发生此类错误及其成因的可能性。作为回应,安全药物实践研究所(ISMP)在2011年10月召开了由60位该领域邀请专家组成的峰会,目的是通过共识建立确保安全制备复方无菌制剂所需的指导方针,安全实践和标准操作程序制剂,尤其是静脉内混合物。由此产生的指导方针分为14个核心流程:政策和程序,订单输入和验证,药品存储,产品和供应品的组装,配料,药品短缺期间的药品保存,源/大容器的准备,所使用的技术/自动化,IV工作流程软件,自动IV复合设备,质量控制/最终验证,产品标签,记录保存和员工管理。它们也分为3个级别:强制,标准和推荐。认为本文中介绍的准则适用于任何制备无菌复合产品的医疗机构。该小组的共识是,遵守这些指南将提高无菌产品配制的安全性,并减少接受这些产品的患者的有害错误。将这些指南纳入卫生保健组织的无菌配合操作是提高患者安全性的重要组成部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号